References
- Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-22. 10.1002/hep.2419921374666
- Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42. 10.1053/jhep.2003.5004712540794
- Idee JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol 2013; 88: 530-49. 10.1016/j.critrevonc.2013.07.00323921081
- Nakakuma K, Tashiro S, Hiraoka T, Uemura K, Konno T, Miyauchi Y, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983; 52: 2193-200.10.1002/1097-0142(19831215)52:12<;2193::AID-CNCR2820521203>3.0.CO;2-R6196102
- Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res 1984; 44: 2115-21.6324996
- Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985; 154: 25-9. 10.1148/radiology.154.1.29811142981114
- Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver. Semin Intervent Radiol 2008; 25: 77-85. 10.1055/s-2008-107668521326548
- Jinno K, Moriwaki S, Tanada M, Wada T, Mandai K, Okada Y. Clinicopathological study on combination therapy consisting of arterial infusion of Lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992; 31(Suppl): S7-12.10.1007/BF006870971333912
- Choi BI, Kim HC, Han JK, Park JH, Kim YI, Kim, ST, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 1992; 182: 709-13. 10.1148/radiology.182.3.13111161311116
- Takayasu K, Arii S, Matsuo N, Ryu M, Takasaki K, Sato M, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175: 699-704. 10.2214/ajr.175.3.175069910954453
- Kwan SW, Fidelman N, Ma E, Kerlan RK, Jr., Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012; 18: 727-36. 10.1002/lt.2341322344899
- Imaeda T, Yamawaki Y, Seki M, Goto H, Iinuma G, Kanematsu M, et al. Lipiodol retention and massive necrosis after Lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 1993; 16: 209-13.10.1007/BF026029628402781
- Takayasu K, Muramatsu Y, Maeda T, Iwata R, Furukawa H, Muramatsu Y, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176: 681-8. 10.2214/ajr.176.3.176068111222205
- Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014; 20: 6995-7004. 10.3748/wjg.v20.i22.699524944494
- Kinugasa H, Nouso K, Takeuchi Y Yasunaka T, Onishi H, Nakamura S, et al. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol 2012; 47: 421-6. 10.1007/s00535-011-0492-922048256
- European Association for the Study of The Liver, European Organisation for Rsearch and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43. 10.1016/j.jhep.2011.12.00122424438
- The Japan Society of Hepatology. Clinical Practice Guidelines for Hepatocellular Carcinoma 2013. [citated 2015 Sep 04]. http://www.jsh.or.jp/English/guidelines_en/Guidelines_for_hepatocellular_carcinoma_2013.
- Becker G. Creating comparability among reliability coefficients: the case of Cronbach alpha and Cohen kappa. Psychol Rep 2000; 87: 1171-82. 10.2466/pr0.2000.87.3f.117111272758
- Harvill LM. Standard error of measurement. Educational measurement: Issues and practice 1991; 10: 33-41. 10.1111/j.1745-3992.1991.tb00195.x
- Herber S, Biesterfeld S, Franz U, Schneider J, Thies J, Schuchmann M, et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31: 768-77. 10.1007/s00270-007-9270-818196335
- Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, et al. Three-dimensional evaluation of Lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol 2014; 21: 393-9. 10.1016/j.acra.2013.11.00624507426
- Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013; 105: 59-68. 10.1093/jnci/djs46423150720
- Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010; 194: 830-7. 10.2214/AJR.09.330820173167